Febrile Neutropenia: Treatment

Definition

• Fever: single oral temperature ≥38.3°C (101°F), or ≥38.0°C (100.4°F) sustained for >1 hour
• Neutropenia: ANC <1000/mm³; severe <500/mm³; profound <100/mm³

Step 1 - Risk Stratification

• Profound neutropenia expected to last >7-10 days
• Inpatient at time of fever onset
• Hemodynamic instability / septic shock
• Acute leukemia or uncontrolled cancer
• Evidence of organ failure (renal, hepatic)
• Pneumonia, severe soft tissue infection, or central line infection
• Abdominal pain, neurologic changes, severe mucositis

• Neutropenia expected to resolve within 7 days
• No comorbid medical conditions
• Well-appearing, no peritoneal signs, normal CXR
• Low MASCC score

Step 2 - Initial Evaluation (within 60 minutes)

• Two blood cultures: one from each lumen of central venous catheter + one peripheral site (or two peripheral sites if no CVC)
• CBC, electrolytes, renal/hepatic function, serum lactate
• Urinalysis + urine culture
• Chest radiograph (note: poorly sensitive for infiltrates in neutropenia)
• Additional cultures (sputum, stool, wound) if clinically indicated
• CT chest/abdomen/pelvis if no source identified on routine workup
• Influenza PCR (in season) - rapid antigen test has insufficient sensitivity
• Consider C. difficile testing if diarrhea present
• Careful physical exam: mouth, sinuses, lungs, skin, perineum/anus, nail beds, all catheter sites. Avoid digital rectal exam until after first antibiotic dose

Step 3 - Empiric Antibiotic Therapy

Inpatient - Monotherapy (first-line)

• Use pip/tazo, cefepime, or ceftazidime if no known MDR colonization
• Use imipenem or meropenem if known ESBL-producing organism colonization
• Pseudomonas coverage must always be included

When to Add Vancomycin (not routine)

• Hemodynamic instability / septic shock
• Catheter-related infection with hypotension
• Skin or soft tissue infection (cellulitis)
• Known MRSA or penicillin-resistant pneumococcal colonization
• Positive blood culture for gram-positive organisms (before final ID/sensitivities)
• Severe mucositis with prior fluoroquinolone prophylaxis
• Institutions with high prevalence of MRSA, VSE, or S. mitis

Penicillin Allergy

• Minor allergy: Cefepime, meropenem, or imipenem/cilastatin can usually be given safely
• Severe/anaphylactic allergy: Aztreonam + vancomycin. Avoid empiric fluoroquinolones for gram-negative coverage in this setting

Source-Directed Additions

Outpatient (low-risk patients only)

Step 4 - Antifungal Therapy

• Amphotericin B (or lipid formulations) is the drug of choice for invasive fungal infections
• Micafungin or voriconazole may be used for specific fungal pathogens (preferred when amphotericin toxicity is a concern)

Step 5 - Duration of Therapy

• Median fever duration after starting antibiotics: ~2 days (low-risk) vs. 5-7 days (high-risk)
• Reassess at 2-4 days before changing regimen (earlier if clinical deterioration or culture results)
• Continue antibiotics until:
  • Documented infection has clinically resolved AND
  • Patient has been afebrile for ≥2 days AND
  • ANC has recovered to >500/mm³

Step 6 - Antibiotic De-escalation

Special Populations

Sildenafil for Erectile Dysfunction in Diabetic Men

Why Diabetes Causes ED

• Prevalence: Men with type 2 DM develop ED approximately 3× more frequently than the general population, and ED can be the presenting symptom of undiagnosed diabetes - Smith & Tanagho's General Urology, p. 625
• Mechanisms: Diabetes damages multiple systems simultaneously:
  • Microvascular disease - small vessel damage to cavernous arteries reduces arterial inflow
  • Cavernous nerve terminal damage - autonomic neuropathy impairs neurogenic NO release
  • Endothelial dysfunction - reduced eNOS activity, decreased NO production
  • Smooth muscle changes - cavernous smooth muscle fibrosis and reduced relaxation capacity
  • Veno-occlusive dysfunction - impaired compression of penile venous plexus
• The net result: decreased responsiveness to PDE5 inhibitors due to the combined neurovascular damage - Smith & Tanagho's, p. 625

Mechanism of Action of Sildenafil

1. Sexual stimulation triggers nitric oxide (NO) release in the corpus cavernosum
2. NO activates guanylyl cyclase → converts GTP to cGMP
3. cGMP causes smooth muscle relaxation via reduced intracellular Ca²⁺ → increased blood inflow → erection
4. PDE-5 normally degrades cGMP, terminating erection
5. Sildenafil inhibits PDE-5 → prevents cGMP degradation → prolongs and amplifies the erectile response

Sildenafil Dosing and Pharmacokinetics

Efficacy in Diabetic Patients

• Efficacy is lower than in non-diabetic men: Sildenafil fails to produce adequate erections in approximately 50% of men with long-standing, insulin-dependent diabetes compared to a ~25-30% failure rate in the general ED population - Kaplan & Sadock's Comprehensive Textbook, p. 6140
• Despite this, it remains the first-line pharmacological treatment alongside the other PDE5 inhibitors
• Systematic reviews confirm efficacy of sildenafil citrate for ED in men with diabetes mellitus - Campbell-Walsh Wein Urology, p. 185

• Diabetic neuropathy reduces the neurogenic NO signal that sildenafil depends on to amplify
• Endothelial dysfunction reduces the eNOS contribution to NO
• Advanced glycation end-products impair smooth muscle relaxation
• The longer the duration and poorer the control of diabetes, the lower the response rate

Clinical Use in Diabetic Patients

Before Starting

• Check fasting glucose and HbA1c (better glycemic control improves ED outcomes)
• Lipid profile (dyslipidemia worsens vasculogenic ED)
• Morning testosterone (calculated free T) - hypogonadism is common in type 2 DM and reduces PDE5i response; replace testosterone if low
• Cardiovascular risk assessment is mandatory - diabetic men are at high cardiovascular risk; assess whether sexual activity is safe (must be able to perform ≥6 METs without symptoms)
• Use IIEF-5 questionnaire for baseline severity scoring - Smith & Tanagho's, p. 626

Contraindications

Key Adverse Effects

• Headache (most common), flushing, dyspepsia, nasal congestion
• Visual disturbance - blue-tinted vision (cyanopsia) due to mild PDE-6 inhibition in the retina; transient
• Nonarteritic anterior ischemic optic neuropathy (NAION) - rare but serious; avoid in patients with optic pathology
• Sudden hearing loss - rare association

When Sildenafil Alone is Insufficient in Diabetes

Optimize Glycemic Control First

Testosterone Replacement + Sildenafil

Alternative PDE5 Inhibitors

• Tadalafil (Cialis): longer half-life (~18 hours), effective for up to 36 hours, once-daily dosing option (5 mg/day) available - avoids timing pressure and may provide more consistent coverage; food does not affect absorption
• Vardenafil, Avanafil: similar efficacy to sildenafil; avanafil has fastest onset (30 min)

Intracavernosal Injection (alprostadil)

• Acts locally, independent of the neurogenic NO pathway
• Can produce erections without sexual stimulation
• Prostaglandin E1 - direct cavernous smooth muscle relaxant
• Useful in diabetic men who fail oral PDE5 inhibitors due to severe autonomic neuropathy

Combination Therapy Options

• Oral PDE5i + intracavernous alprostadil
• Oral PDE5i + vacuum erection device
• Oral PDE5i + transurethral alprostadil (MUSE)
• Tadalafil 5 mg daily + sildenafil 50 mg on-demand (for partial responders) - Campbell-Walsh, Combination Therapies

Low-Intensity Extracorporeal Shockwave Therapy (Li-ESWT)

Penile Prosthesis

Summary: Step-Up Approach in Diabetic ED

1. Lifestyle + glycemic optimization - weight loss, HbA1c control, stop smoking
2. Check testosterone - replace if hypogonadal before or alongside PDE5i
3. Sildenafil 50 mg (or other PDE5i) on demand - titrate to 100 mg if tolerated and needed
4. Switch or add: tadalafil daily dosing, or combine with testosterone replacement
5. Intracavernosal alprostadil or vacuum erection device if PDE5i fails
6. Combination therapies (PDE5i + alprostadil, PDE5i + VED)
7. Penile prosthesis for refractory cases